Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.53 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 2/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4426983 | 1.00 | MAOB (0.53) | MAOBPARP10MAOASCN9AGRM5 | |
| SCHEMBL4427215 | 0.88 | MAOB (0.46) | MAOBPARP10MAOASCN9ANR4A2 | |
| SCHEMBL3505057 | 0.88 | MAOB (0.46) | MAOBPARP10MAOASCN9ANR4A2 | |
| SCHEMBL3505001 | 0.87 | MAOB (0.60) | MAOBPARP10MAOASCN9AGRM5 | |
| SCHEMBL3504999 | 0.87 | MAOB (0.60) | MAOBPARP10MAOASCN9AGRM5 | |
| SCHEMBL3505994 | 0.86 | MAOB (0.64) | MAOBPARP10MAOASCN9AGRM5 | |
| SCHEMBL4429877 | 0.86 | MAOB (0.64) | MAOBPARP10MAOASCN9AGRM5 | |
| SCHEMBL3505993 | 0.86 | MAOB (0.64) | MAOBPARP10MAOASCN9AGRM5 | |
| SCHEMBL4428368 | 0.84 | GRM5 (0.54) | MAOBPARP10MAOASCN9AGRM5 | |
| SCHEMBL4553416 | 0.84 | GRM5 (0.54) | MAOBPARP10MAOASCN9AGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951884-B2 | Fluorobenzamides and uses thereof | HOFFMANN-LA ROCHE INC. (US) | 2005-10-04 | — | — | US | claimed |
| US-20030236304-A1 | Fluorobenzamides and uses thereof | F. HOFFMANN-LA ROCHE AG (CH) | 2003-12-25 | — | — | US | claimed |
| EP-1515926-B1 | FLUOROBENZAMIDES SUITABLE FOR THE TREATMENT OF ALZHEIMER'S DISEASE OR SENILE DEMENTIA | HOFFMANN LA ROCHE (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-6951884-B2 | Fluorobenzamides and uses thereof | HOFFMANN-LA ROCHE INC. (US) | 2005-10-04 | — | — | US | disclosed |
| US-20030236304-A1 | Fluorobenzamides and uses thereof | F. HOFFMANN-LA ROCHE AG (CH) | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236304-A1 | Fluorobenzamides and uses thereof | MAOB, MAOA, BCHE | MAOB 1/4885PARP10 1686/4885MAOA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.